How the Math of Cancer Drug Profits and Drug Approval Would Support Testing Inert Substances
Executive Summary The financial rewards of introducing new cancer drugs are so large versus development costs that a drug company could make money testing inert substances. Introduction Reviewing the math of incentives and costs for developing new cancer drugs is highly instructive in understanding how the industry works and why so many cancer treatments are…